Colorectal Neoplasms Clinical Trial
Official title:
FIT Mailing Protocol-For Cancer Screening Navigation
We plan to study whether the impact of offering the choice of a pre-colonoscopy physician
visit or direct referral to colonoscopy will increase adherence to colonoscopy relative to
usual care in a large fecal immunochemical test (FIT) mailing campaign.
We will evaluate two study options, usual care during which patients will be required to
have an office visit with wither a PCP or a Gastroenterologist prior to being scheduled for
a colonoscopy, or a choice where patients will be given the option of a pre-colonoscopy
visit with a gastroenterologist or PCP vs. direct referral for a colonoscopy.
In these two options we will examine colonoscopy adherence, adequacy of triage, patient
satisfaction, colonoscopy outcomes (no show rate, prep quality, and pain during colonoscopy)
and how insurance coverage, gender, race, education or patient understanding of colon cancer
screening message during the navigation process might impact outcomes.
A total of 13,392 patients will be invited to participate in the study. Approximately 2500
patients will be enrolled in the study every month for 4 months. This sampling plan will
enable sufficient statistical power (at least .80) to conduct the analyses of the objectives
using logistic regression.
At the time of enrollment into the study, an educational brochure and a letter will be sent
to all potential participants advising them that they may not be up to date in colon cancer
screening and that they will be receiving a free FIT test in the mail in a couple weeks. The
letter will advise them that they will be participating in a study that Renown is doing to
improve the ability to diagnose early colon cancer and that they will be contacted by Renown
with their results and also any additional recommendations if the FIT is positive. If they
have questions or do not want to participate, there is a number for potential participants
to call for more information or to opt out. Patients that choose not to participate in the
study who would still like to complete the FIT screening kit, will be informed that they
will be responsible to pay for the FIT test (about $25) following Renown's standard
operating procedures.
2 weeks after the initial letter, all newly enrolled patients will receive a mailing
including a FIT test, an educational brochure, instructions on how to collect the FIT test
and a Thank You letter for participating.
An initial automated telephone message will be left for each patient at the time of the
mailing reminding them to submit their stool FIT. At 2 and 3 weeks after the FIT mailing all
patients medical records will be reviewed and those who have not yet returned their stool
FIT will receive an automated telephone call reminder to mail in their stool FIT.
At 4 weeks all patients who have not yet returned their stool FIT will be contacted by phone
and those that are able to be reached and agree to submit the stool FIT will be mailed a 2nd
stool FIT if needed. If the stool FIT is not submitted by 2 months of the mailing, the
patient will be listed as not returning a FIT.
All patients who have returned a stool FIT with a negative result will be provided their
results by letter.
The patients PCP will be also provided the positive or negative results by letter.
All patients with a positive stool FIT will be randomized into either Usual Care or Choice
study groups. The two study groups will be matched by gender, race/ethnicity,
Spanish-speakers, and rural/urban location.
Patients in Group 1 (Usual Care) who have a positive result will be contacted by phone by
the Nurse Navigator with their results, receive some education about the significance of a +
stool FIT relative to colon cancer screening and advised to make an appointment with a PCP
or Gastroenterologist to discuss the results and possibly be referred for colonoscopy. If
they do not have a PCP they will receive assistance in being referred to one. They will be
asked to complete a telephone questionnaire that explores patient demographics (education,
race, income, prior colonoscopy etc) in Spanish or English. Patients' EPIC electronic
medical records will be monitored to see if they have made an appointment within 2 days of
getting their results. If not, they will receive 2 attempted live telephone reminders
followed by a certified letter. If a patient is referred to a GI consult, and fails to
schedule an appointment within 1 month, GI will notify the patients Renown PCP of the failed
appointment.
Patients in Group 1 with a positive result who cannot be reached by phone will receive a
certified letter with their results with instructions to contact the Study Navigator to
arrange further testing.
Patients in Group 2 (Choice) who have a positive FIT result will be contacted by phone by
the Nurse Navigator with their results, receive some education about the significance of a +
stool FIT relative to colon cancer screening and given the choice to either schedule an
appointment with a PCP or Gastroenterologist to discuss their results, or will receive
direct referral to Gastroenterology Consultants for a colonoscopy. They will be asked to
complete a telephone questionnaire that explores patient demographics (education, race,
income, prior colonoscopy) in Spanish or English. Patients will then receive assistance and
monitoring as in that described above for Group 1 depending upon whether they are referred
for an office visit/consultation vs. a direct referral for a colonoscopy.
Patients in Group 2 with a positive result who cannot be reached by phone will receive a
certified letter with their results with instructions to contact the Study Navigator to
arrange further testing.
Patients who are referred directly for a colonoscopy will be contacted by phone by a
scheduler at Gastroenterology Consultants and be asked questions to determine the best bowel
preparation and sedation for them (conscious sedation with fentanyl and versed vs. propofol,
and to insure that the patient has no significant co-morbidities that might require a
pre-colonoscopy visit for medical assessment (anticoagulants, severe lung disease, recent
MI, bleeding disorder).
Additionally, those that are referred for a direct colonoscopy and fail to schedule or show
for their appointment will be referred back to the Renown Nurse Navigator for 2 attempts at
a live call then a certified letter.
All patients in group 2 who have not yet had a colonoscopy 6 months after they were
initially given their results will again be contacted by phone by a Navigator and again
encouraged to have colonoscopy or at minimum to discuss the procedure/FIT results with
either their physician or a Gastroenterologist and be offered assistance to schedule those
appointments.
Patients in both groups will have 1 year from the date their initial FIT test is mailed to
obtain a colonoscopy as recorded in the EPIC EMR.
All patients with a positive stool FIT who have completed the study either by having a
colonoscopy or by not having a colonoscopy at the end of the study period will be mailed a
questionnaire assessing various quality parameters of the colon cancer screening experience
with a stamped self addressed envelope for return and Thank You letter for their
participation including a $10 Amazon gift certificate as a token of appreciation for their
time. If the questionnaire is not returned within 2 weeks, they will be sent a 2nd
questionnaire and reminder letter. After 2 more weeks, if the questionnaire is not returned
the research assistant will contact the patient to offer the choice to complete the survey
over the telephone.
To accommodate Spanish speaking only patients, all documents mailed to patients will be
written both in English and Spanish versions and Spanish translators will be available to
speak with patients by phone to respond to questions or to go over the questionnaires.
Other Items A script will be used for any participants who call with questions (see "Script
if participant calls").
To protect participant's identity, only de-identified data will be reviewed by the UNR
co-investigator (Paul Devereux). The de-identified data will be stored on a
password-protected computer in Paul Devereux's locked office. The data will be transferred
to Paul Devereux using a password-protected USB flash drive. Data will not contain, names,
addresses, dates of birth, or Renown ID numbers.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
| Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
| Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
| Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
| Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
| Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
| Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
| Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
| Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
| Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
| Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
| Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
| Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
| Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
| Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
| Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
| Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
| Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
| Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |